A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Durvalumab (Primary) ; Ibrutinib
- Indications Advanced breast cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 02 Sep 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.